Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Avidity Biosciences, Inc. - Common Stock (NQ:RNA)

71.87 -0.10 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avidity Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium ↗
Via Stocktwits
News headline image
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal ↗
The company is focused on treatments for forms of muscular dystrophy. 
Via Investor's Business Daily
News headline image
Veritex Holdings, Sequans Communications, Canaan And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Expert Outlook: Avidity Biosciences Through The Eyes Of 11 Analysts ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts ↗
 
Via Benzinga
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks ↗
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ... 
Via Benzinga
News headline image
Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Analyst Expectations For Avidity Biosciences's Future ↗
 
Via Benzinga
News headline image
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial ↗
Avidity shares early del-brax FSHD data showing improved mobility, strength, and safety; Phase 3 FORWARD trial now underway. 
Via Benzinga
News headline image
12 Analysts Assess Avidity Biosciences: What You Need To Know ↗
 
Via Benzinga
News headline image
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
News headline image
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock ↗
 
Via Benzinga
News headline image
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences ↗
 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Avidity Biosciences ↗
 
Via Benzinga
News headline image
Assessing Avidity Biosciences: Insights From 10 Financial Analysts ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences ↗
 
Via Benzinga
News headline image
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 ↗
Avidity's del-zota met key Phase 1/2 trial goals in DMD44, shows strong exon skipping, dystrophin restoration and creatine kinase reduction. 
Via Benzinga
News headline image
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
Topics Stocks
News headline image
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
News headline image
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
Topics Stocks
News headline image
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News ↗
The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb. 
Via Investor's Business Daily
News headline image
Evaluating Avidity Biosciences: Insights From 10 Financial Analysts ↗
 
Via Benzinga
News headline image
Unveiling 7 Analyst Insights On Avidity Biosciences ↗
 
Via Benzinga
News headline image
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings) ↗
 
Via Benzinga
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Avidity Biosciences Zoomed to a 12% Gain This Week ↗
The company's most promising pipeline program can continue unabated. 
Via The Motley Fool
News headline image
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases ↗
Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular... 
Via Benzinga
News headline image
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease ↗
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga
News headline image
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.